These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 34936714)
1. A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands, New Drug Leads and PROTACs. Huber ME; Toy L; Schmidt MF; Vogt H; Budzinski J; Wiefhoff MFJ; Merten N; Kostenis E; Weikert D; Schiedel M Angew Chem Int Ed Engl; 2022 Mar; 61(12):e202116782. PubMed ID: 34936714 [TBL] [Abstract][Full Text] [Related]
2. Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the Chemokine Receptor CCR2. Toy L; Huber ME; Schmidt MF; Weikert D; Schiedel M ACS Chem Biol; 2022 Aug; 17(8):2142-2152. PubMed ID: 35838163 [TBL] [Abstract][Full Text] [Related]
3. Intracellular allosteric antagonism of the CCR9 receptor. Oswald C; Rappas M; Kean J; Doré AS; Errey JC; Bennett K; Deflorian F; Christopher JA; Jazayeri A; Mason JS; Congreve M; Cooke RM; Marshall FH Nature; 2016 Dec; 540(7633):462-465. PubMed ID: 27926729 [TBL] [Abstract][Full Text] [Related]
4. Small Molecule Tools to Study Cellular Target Engagement for the Intracellular Allosteric Binding Site of GPCRs. Huber ME; Toy L; Schmidt MF; Weikert D; Schiedel M Chemistry; 2023 Jan; 29(1):e202202565. PubMed ID: 36193681 [TBL] [Abstract][Full Text] [Related]
5. Development of fluorescent peptide G protein-coupled receptor activation biosensors for NanoBRET characterization of intracellular allosteric modulators. Farmer JP; Mistry SN; Laughton CA; Holliday ND FASEB J; 2022 Nov; 36(11):e22576. PubMed ID: 36183332 [TBL] [Abstract][Full Text] [Related]
6. The role of the CCL25-CCR9 axis in beta-cell function: potential for therapeutic intervention in type 2 diabetes. Atanes P; Lee V; Huang GC; Persaud SJ Metabolism; 2020 Dec; 113():154394. PubMed ID: 33058852 [TBL] [Abstract][Full Text] [Related]
15. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. Walters MJ; Wang Y; Lai N; Baumgart T; Zhao BN; Dairaghi DJ; Bekker P; Ertl LS; Penfold ME; Jaen JC; Keshav S; Wendt E; Pennell A; Ungashe S; Wei Z; Wright JJ; Schall TJ J Pharmacol Exp Ther; 2010 Oct; 335(1):61-9. PubMed ID: 20660125 [TBL] [Abstract][Full Text] [Related]
16. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Wendt E; Keshav S Clin Exp Gastroenterol; 2015; 8():119-30. PubMed ID: 25897254 [TBL] [Abstract][Full Text] [Related]
17. A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease. Kalindjian SB; Kadnur SV; Hewson CA; Venkateshappa C; Juluri S; Kristam R; Kulkarni B; Mohammed Z; Saxena R; Viswanadhan VN; Aiyar J; McVey D J Med Chem; 2016 Apr; 59(7):3098-111. PubMed ID: 26987013 [TBL] [Abstract][Full Text] [Related]
18. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Wermers JD; McNamee EN; Wurbel MA; Jedlicka P; Rivera-Nieves J Gastroenterology; 2011 May; 140(5):1526-35.e3. PubMed ID: 21300065 [TBL] [Abstract][Full Text] [Related]
19. Agonist-selective recruitment of engineered protein probes and of GRK2 by opioid receptors in living cells. Stoeber M; Jullié D; Li J; Chakraborty S; Majumdar S; Lambert NA; Manglik A; von Zastrow M Elife; 2020 Feb; 9():. PubMed ID: 32096468 [TBL] [Abstract][Full Text] [Related]
20. Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease. Zhang J; Romero J; Chan A; Goss J; Stucka S; Cross J; Chamberlain B; Varoglu M; Chandonnet H; Ryan D; Lippa B Bioorg Med Chem Lett; 2015 Sep; 25(17):3661-4. PubMed ID: 26117562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]